Last checked at 18 Feb 2013 17:13
February 18, 2013
Issue of Equity: Stock Dividend
Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) announces that the stock dividend proposed on 18 May 2012 and passed by shareholders at the Annual General Meeting on 1 July 2012 has been credited to shareholder accounts.
The Company has applied for admission of 11,856,062 new GDRs issued in respect of the stock dividend to be admitted to trading on the London Stock Exchange's AIM market and admission is expected to occur on or around 22 February 2013.
Following admission, the total issued share capital of the Company will be 304,639,050 ordinary shares of Taka 10 ("Ordinary Shares"), of which 68,313,501 will be represented by GDRs, each representing one Ordinary Share of Taka 10. The new Ordinary Shares will rank pari passu in all respects with the existing issued Ordinary Shares, all having voting rights.
Ends
For further enquiries please contact:
Beximco Pharma
Nazmul Hassan MP, Managing DirectorTel: +880 2 861 9151, ext.2080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel; +880 2 8618220-1, Ext 1140
Libertas Capital Corporate Finance
Thilo Hoffmann
Tel: +44 (0)20 7569 9650
FTI Consulting
Simon Conway / Susan Stuart / Victoria Foster-MitchellTel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.